FAQ on the Unchanged Prevalence of Psoriasis in the U.S. and Related Concerns
Summary
A recent analysis reveals the prevalence of psoriasis in the U.S. has remained at 3% over the past decade, highlighting ongoing concerns and the need for improved treatments and diagnostic access.
What is the main finding of the recent analysis on psoriasis in the U.S.?
The main finding is that the general percentage of adults in the U.S. diagnosed with psoriasis has remained unchanged at 3% over the past 10 years, as reported in the Journal of American Academy of Dermatology.
Why is the unchanged prevalence of psoriasis concerning?
Despite the stable prevalence, there are concerns about the number of people suffering from psoriasis and the urgent need for improved access to diagnostic services and effective treatments.
How are companies like Soligenix Inc. contributing to psoriasis treatment?
Soligenix Inc. is among the firms undertaking R&D efforts to develop effective treatments against psoriasis, as mentioned in the content.
Where can I find more information about the study on psoriasis prevalence?
More information can be found in the analysis published in the Journal of American Academy of Dermatology and through several points of concern highlighted by investigators.
What is BioMedWire’s role in disseminating information about psoriasis and other biomedical developments?
BioMedWire is a specialized communications platform focusing on the latest developments in Biotechnology, Biomedical Sciences, and Life Sciences, providing access to a vast network of wire solutions, article and editorial syndication, and social media distribution to reach a wide audience.
How can I receive alerts from BioMedWire?
You can receive SMS alerts from BioMedWire by texting ‘Biotech’ to 888-902-4192 (U.S. Mobile Phones Only).
Where can I find more information about BioMedWire and its services?
For more information, visit https://www.BioMedWire.com, where you can also find full terms of use and disclaimers applicable to all content provided by BMW.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 108395